Hydroxychloroquine Treatment of Rheumatoid Arthritis
Overview
Authors
Affiliations
A variety of placebo-controlled and open studies have demonstrated the effectiveness of hydroxychloroquine in the treatment of rheumatoid arthritis. The excellent responses to recurrent treatment in a sample patient illustrate the value of hydroxychloroquine. Because low daily doses of hydroxychloroquine are associated with greater ophthalmologic safety, it would be advantageous to use the smallest effective daily dose, but there are no published controlled efficacy studies using daily doses of less than 400 mg. Hydroxychloroquine may best be employed to treat patients with new onset of disease or those in whom disease is not rapidly progressive. Great potential exists for the use of hydroxychloroquine in combination therapy, but optimal utilization of combination regimens will require performances of additional controlled studies.
Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.
Fox R, Fox C, McCoy S Expert Opin Emerg Drugs. 2023; 28(2):107-120.
PMID: 37127914 PMC: 10330372. DOI: 10.1080/14728214.2023.2209720.
Rath M, Keny S, Upadhyaya H, Adhikari S Radiat Phys Chem Oxf Engl 1993. 2023; 206:110785.
PMID: 36685709 PMC: 9840095. DOI: 10.1016/j.radphyschem.2023.110785.
de Reus Y, Hagedoorn P, Sturkenboom M, Grasmeijer F, Bolhuis M, Sibum I PLoS One. 2022; 17(8):e0272034.
PMID: 35930536 PMC: 9355221. DOI: 10.1371/journal.pone.0272034.
Does hydroxychloroquine still have any role in the COVID-19 pandemic?.
Schilling W, White N Expert Opin Pharmacother. 2021; 22(10):1257-1266.
PMID: 33724123 PMC: 7989952. DOI: 10.1080/14656566.2021.1898589.
White N, Watson J, Hoglund R, Chan X, Cheah P, Tarning J PLoS Med. 2020; 17(9):e1003252.
PMID: 32881895 PMC: 7470382. DOI: 10.1371/journal.pmed.1003252.